Literature DB >> 19939624

Profiling Fragile X Syndrome in males: strengths and weaknesses in cognitive abilities.

M J W Van der Molen1, M Huizinga, H M Huizenga, K R Ridderinkhof, M W Van der Molen, B J C Hamel, L M G Curfs, G J A Ramakers.   

Abstract

The present study examined the cognitive profile in Fragile X Syndrome (FXS) males, and investigated whether cognitive profiles are similar for FXS males at different levels of intellectual functioning. Cognitive abilities in non-verbal, verbal, memory and executive functioning domains were contrasted to both a non-verbal and verbal mental age reference. Model-based cluster analyses revealed three distinct subgroups which differed in level of functioning, but showed similar cognitive profiles. Results showed that cognitive performance is particularly weak on measures of reasoning- and performal abilities confined to abstract item content, but relatively strong on measures of visuo-perceptual recognition and vocabulary. Further, a significant weakness was found for verbal short-term memory. Finally, these results indicated that the choice of an appropriate reference is critically important in examining cognitive profiles. The pattern of findings that emerged from the current cognitive profiling of FXS males was interpreted to suggest a fundamental deficit in executive control. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19939624     DOI: 10.1016/j.ridd.2009.10.013

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  25 in total

Review 1.  Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome.

Authors:  Lawrence K Fung; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2015-12-18       Impact factor: 13.382

Review 2.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

3.  Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

Authors:  S J Bonasera; T R Chaudoin; E H Goulding; M Mittek; A Dunaevsky
Journal:  Genes Brain Behav       Date:  2017-03-29       Impact factor: 3.449

4.  Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome.

Authors:  Ragunathan Padmashri; Benjamin C Reiner; Anand Suresh; Elizabeth Spartz; Anna Dunaevsky
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

Review 5.  Fragile X-associated disorders: a clinical overview.

Authors:  Anne Gallagher; Brian Hallahan
Journal:  J Neurol       Date:  2011-07-12       Impact factor: 4.849

Review 6.  Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.

Authors:  Lawrence K Fung; Antonio Y Hardan
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 7.  Public Health Literature Review of Fragile X Syndrome.

Authors:  Melissa Raspa; Anne C Wheeler; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

8.  Early social communication in infants with fragile X syndrome and infant siblings of children with autism spectrum disorder.

Authors:  Laura J Hahn; Nancy C Brady; Lindsay McCary; Lisa Rague; Jane E Roberts
Journal:  Res Dev Disabil       Date:  2017-10-15

9.  The cognitive developmental profile associated with fragile X syndrome: A longitudinal investigation of cognitive strengths and weaknesses through childhood and adolescence.

Authors:  Eve-Marie Quintin; Booil Jo; Scott S Hall; Jennifer L Bruno; Lindsay C Chromik; Mira M Raman; Amy A Lightbody; Arianna Martin; Allan L Reiss
Journal:  Dev Psychopathol       Date:  2015-12-09

Review 10.  Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome.

Authors:  Latha Soorya; Jill Leon; M Pilar Trelles; Audrey Thurm
Journal:  Clin Neuropsychol       Date:  2017-12-21       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.